LepTrim patent is based on data collected at the University of Minnesota LepTrim matches up to US Patent No.6,899,892 in which the invention provides a method and composition for reducing the level of Leptin in the bloodstream and correspondingly reduction in the percentage of body fat.
- The patent also claims sufficient reductions in the level of serum Leptin in the bloodstream to beneficial or efficacious levels in approximately three to six weeks.
- LepTrim has the attached rights of employing the patent number on labels and brochures. At efficacious levels, suggested structure-function or marketing statements may include the following:
- Assists in promoting fat loss
(Supported by US Patent 6,899,892 and references 1, 2 and 3 ).
- Assists in promoting a lower percentage of body fat
(Supported by US Patent 6,899,892 and references 1, 2, 3 and 4).
- Promotes the reduction of stored fat by increasing fatty acid utilization in the fat cell (Supported by references 4 and 5).
- Promotes the reduction of fat and an enhanced muscle to fat ratio
(Supported by references 1, 2, 3 and 4).
- Promotes the regulation of energy balance allowing for improved mental energy (Supported by references 6 and 7).
[table id=1 /]